BeOne Medicines (BEIGF) Net Cash Flow Growth (3y) (2018 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Net Cash Flow Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | 38.95% |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | -49.89% |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | 33.59% |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | 38.53% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | -51.84% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 1.06% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | 18.67% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 95.24% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 106.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 106.37% |
| Mar 31, 2026 | 38.47% |
| Dec 31, 2025 | 47.67% |
| Sep 30, 2025 | 89.73% |
| Jun 30, 2025 | -3.87% |
| Mar 31, 2025 | -43.94% |
| Dec 31, 2024 | -26.15% |
| Sep 30, 2024 | 29.44% |
| Jun 30, 2024 | -11.34% |
| Mar 31, 2024 | -38.89% |
| Dec 31, 2023 | 38.75% |
| Sep 30, 2023 | -71.78% |
| Jun 30, 2023 | 53.88% |
| Mar 31, 2023 | -31.13% |
| Dec 31, 2022 | -10.52% |
| Sep 30, 2022 | -118.07% |
| Jun 30, 2022 | 17.43% |
| Mar 31, 2022 | -41.99% |
| Dec 31, 2021 | 373.36% |
| Sep 30, 2021 | -53.32% |